<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Syneron Medical Limited</title>
	<atom:link href="http://www.stockbloghub.com/tag/syneron-medical-limited/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SLTM) Solta Medical Reports LipoSonix Approval</title>
		<link>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028</link>
		<comments>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028#comments</comments>
		<pubDate>Thu, 27 Oct 2011 17:26:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86028</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) reported that Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), has won the U.S. approval for the second-generation LIPOSONIX system for non-invasive waist circumference reduction. Solta announced, in September 2011, the acquisition of Medicis Technologies Corporation in a deal worth $35 million. The acquisition, which is expected to be completed in fourth-quarter 2011, provides Solta with Medicis’ LIPOSONIX system which uses advanced non-invasive ultrasound energy to reduce abdominal fat. Under the agreement, Solta will pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLTM) Solta Medical Buying Medicis Unit</title>
		<link>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359</link>
		<comments>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:05:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83359</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) has agreed to acquire Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), in a deal worth roughly $35 million. Under the agreement, Soltawill pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial milestones. The acquisition, which is subject to customary closing conditions including antitrust clearance, is expected to close in fourth-quarter 2011. Solta plans to finance the transaction through its existing cash and credit facilities. The acquisition provides Solta with Medicis’ LIPOSONIX system, which uses advanced non-invasive ultrasound energy to reduce abdominal fat. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CUTR) Cutera&#8217;s GenesisPlus Laser Cleared</title>
		<link>http://www.stockbloghub.com/2011/04/13/cutr-cuteras-genesisplus-laser-cleared/71350</link>
		<comments>http://www.stockbloghub.com/2011/04/13/cutr-cuteras-genesisplus-laser-cleared/71350#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:12:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[CYNO]]></category>
		<category><![CDATA[Cynosure Inc]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71350</guid>
		<description><![CDATA[Medical devices maker Cutera Inc (CUTR) has obtained the 510 (k) clearance from the U.S. Food and Drug Administration (“FDA”) for its GenesisPlus laser for treating onychomycosis (nail fungus). The California-based company’s shares spiked following the news of the approval. Onychomycosis, a fungal infection of the toenails or fingernails, afflicts roughly 35 million Americans. The condition represents clinical symptoms such as discoloration/ thickening of the nail and separation of the nail plate from the nail bed. It is more likely to develop in people with conditions such as diabetes, psoriasis, and peripheral arterial disease (“PAD”). The worldwide market for onychomycosis therapies is estimated to be more than $2 billion. Roughly 20% of the people affected with onychomycosis seek treatment annually in the U.S. Despite its wide prevalence, there are limited ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/cutr-cuteras-genesisplus-laser-cleared/71350/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CUTR) Cutera Offers Preliminary Results</title>
		<link>http://www.stockbloghub.com/2010/01/14/cutr-cutera-offers-preliminary-results/24985</link>
		<comments>http://www.stockbloghub.com/2010/01/14/cutr-cutera-offers-preliminary-results/24985#comments</comments>
		<pubDate>Thu, 14 Jan 2010 22:58:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24985</guid>
		<description><![CDATA[Cutera, Inc. (CUTR) recently reported preliminary revenue results for its fourth quarter. For the quarter, Cutera expects revenues to be roughly $15 million, compared to $17.9 million in the year-ago period. The company is expected to report its fourth quarter and full fiscal 2009 results on Feb 8. Founded in 1998 and based in Brisbane, CA, Cutera, Inc. designs, manufactures and markets laser and light-based aesthetic applications. The company develops innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. The aesthetic market experienced significant growth over the past several years before the start of the recession. Growth was directly impacted by aging baby boomers and their increasing wealth tied to real estate and equity markets. However, the impact of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/cutr-cutera-offers-preliminary-results/24985/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELOS) Syneron Medical&#8217;s Skin Products to Hit Asia</title>
		<link>http://www.stockbloghub.com/2009/11/14/elos-syneron-medicals-skin-products-to-hit-asia/20472</link>
		<comments>http://www.stockbloghub.com/2009/11/14/elos-syneron-medicals-skin-products-to-hit-asia/20472#comments</comments>
		<pubDate>Sat, 14 Nov 2009 23:51:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20472</guid>
		<description><![CDATA[Syneron Medical Ltd. (ELOS) announced the commercial launch of the elure topical skin whitening products in several Asian markets. The company will sell these products through its dermatologists, beauty salons and spas in Asia from the first quarter of 2010. The elure skin whitening product is an enzymatic skin whitening treatment that targets and decomposes melanin to reveal a visibly lighter and exceptionally luminous skin tone. The product uses a naturally occurring bio-active substance, Melanozyme, which decomposes the melanin in a fast and safe manner with no side effects. In the process, Melanozyme is combined with a bio-activator to diminish the dark colored pigment in the skin. The use of Melanozyme eliminates side effects such as skin redness and burning sensation which are seen in the case of other skin ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/elos-syneron-medicals-skin-products-to-hit-asia/20472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELOS) Syneron Medical to Acquire Primaeva Medical</title>
		<link>http://www.stockbloghub.com/2009/10/17/elos-syneron-medical-to-acquire-primaeva-medical/18059</link>
		<comments>http://www.stockbloghub.com/2009/10/17/elos-syneron-medical-to-acquire-primaeva-medical/18059#comments</comments>
		<pubDate>Sat, 17 Oct 2009 21:23:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Candela Corporation]]></category>
		<category><![CDATA[CLZR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Regions Financial Corporation]]></category>
		<category><![CDATA[RF]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18059</guid>
		<description><![CDATA[Syneron Medical Ltd. (ELOS) is set to acquire Primaeva Medical, Inc., an aesthetic technology firm based in Pleasanton, CA. The acquisition is expected to close before the end of 2009. Per the agreement, Syneron will acquire Primaeva for $7 million in cash and up to $23 million of additional payment based on the achievement of certain milestones. The Primaeva acquisition helps Syneron gain access to a new technology for the treatment of wrinkles. The Primaeva product uses the bipolar fractional radiofrequency (RF) energy for the treatment of skin wrinkles and laxity in a selective and predictable manner. Its unique energy delivery mechanism resulted in skin tightening with minimal downtime. An important consideration in skin treatment is the excessive heating of skin. The Primaeva product eliminates this as the treatment temperature ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/17/elos-syneron-medical-to-acquire-primaeva-medical/18059/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

